Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$7.66 -0.3%	$7.08	$5.47 ▼ $11.99	$158.95M	N/A	67,580 shs	16,866 shs
DNTH Dianthus Therapeutics	$23.65 +1.0%	$19.73	$13.36 ▼ $32.27	$761.29M	1.43	323,593 shs	627,849 shs
GYRE Gyre Therapeutics	$7.55 -2.3%	$7.60	$6.11 ▼ $19.00	$727.14M	1.8	164,554 shs	41,866 shs
PROK ProKidney	$2.32 +1.8%	$2.23	$0.46 ▼ $7.13	$679.06M	1.76	5.69 million shs	883,581 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	-3.64%	-9.96%	+35.69%	-23.96%	-9.22%
DNTH Dianthus Therapeutics	+3.17%	+12.33%	+12.92%	+27.56%	-19.19%
GYRE Gyre Therapeutics	+2.66%	-5.85%	+8.87%	-31.04%	-34.10%
PROK ProKidney	-2.15%	-3.80%	-29.19%	+209.40%	-2.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	1.0639 of 5 stars	3.5	0.0	0.0	0.0	1.0	0.8	0.0
GYRE Gyre Therapeutics	0.1194 of 5 stars	0.0	1.0	0.0	0.0	2.1	0.8	0.0
PROK ProKidney	3.7148 of 5 stars	4.2	4.0	0.0	0.0	1.8	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACTU Actuate Therapeutics	3.00	Buy	$20.50	167.62% Upside
DNTH Dianthus Therapeutics	3.00	Buy	$54.00	128.33% Upside
GYRE Gyre Therapeutics	3.00	Buy	N/A	N/A
PROK ProKidney	2.33	Hold	$6.25	169.40% Upside

Current Analyst Ratings Breakdown

Latest ACTU, DNTH, PROK, and GYRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	DNTH Dianthus Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$34.00 ➝ $42.00
8/18/2025	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
8/18/2025	PROK ProKidney	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/15/2025	PROK ProKidney	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $8.00
7/14/2025	PROK ProKidney	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $7.00
7/9/2025	PROK ProKidney	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $9.00
7/2/2025	DNTH Dianthus Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/30/2025	PROK ProKidney	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00 ➝ $1.00
6/3/2025	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$20.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	($0.13) per share	N/A
DNTH Dianthus Therapeutics	$6.24M	122.00	N/A	N/A	$9.42 per share	2.51
GYRE Gyre Therapeutics	$105.76M	6.88	$0.20 per share	38.13	$1.34 per share	5.63
PROK ProKidney	$80K	8,488.30	N/A	N/A	($3.42) per share	-0.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACTU Actuate Therapeutics	-$27.28M	N/A	0.00	∞	N/A	N/A	-19,736.59%	-281.83%	N/A
DNTH Dianthus Therapeutics	-$84.97M	-$3.25	N/A	N/A	N/A	-2,364.56%	-34.72%	-32.72%	11/6/2025 (Estimated)
GYRE Gyre Therapeutics	$12.09M	$0.01	755.76	∞	N/A	4.08%	7.67%	6.19%	N/A
PROK ProKidney	-$61.19M	-$0.57	N/A	N/A	N/A	N/A	N/A	-17.11%	N/A

Latest ACTU, DNTH, PROK, and GYRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ACTU Actuate Therapeutics	-$0.19	-$0.30	-$0.11	-$0.30	N/A	N/A
8/12/2025	Q2 2025	PROK ProKidney	-$0.14	-$0.13	+$0.01	-$0.13	N/A	$0.22 million
8/11/2025	Q2 2025	GYRE Gyre Therapeutics	$0.03	$0.02	-$0.01	$0.04	$30.80 million	$26.77 million
8/7/2025	Q2 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$0.87 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACTU Actuate Therapeutics	N/A	0.73	0.46
DNTH Dianthus Therapeutics	N/A	13.12	13.12
GYRE Gyre Therapeutics	N/A	5.40	4.87
PROK ProKidney	N/A	11.48	11.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACTU Actuate Therapeutics	N/A
DNTH Dianthus Therapeutics	47.53%
GYRE Gyre Therapeutics	23.99%
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
ACTU Actuate Therapeutics	69.34%
DNTH Dianthus Therapeutics	8.15%
GYRE Gyre Therapeutics	10.00%
PROK ProKidney	41.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACTU Actuate Therapeutics	10	20.75 million	6.36 million	N/A
DNTH Dianthus Therapeutics	80	32.19 million	29.57 million	Optionable
GYRE Gyre Therapeutics	40	96.31 million	86.68 million	No Data
PROK ProKidney	3	292.70 million	171.26 million	Optionable

ACTU, DNTH, PROK, and GYRE Headlines

Recent News About These Companies

ProKidney (NASDAQ:PROK) Shares Down 6.9% - What's Next?

4 hours ago | marketbeat.com

ProKidney (NASDAQ:PROK) Stock Price Up 8.1% - Here's What Happened

August 20 at 2:39 PM | marketbeat.com

ProKidney (NASDAQ:PROK) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

August 15, 2025 | marketbeat.com

ProKidney Reports 78 Percent Gain in Q2

August 14, 2025 | theglobeandmail.com

Citi Reaffirms Their Buy Rating on ProKidney (PROK)

August 14, 2025 | theglobeandmail.com

ProKidney reports larger second-quarter loss as key studies continue

August 14, 2025 | journalnow.comJ

ProKidney Corp. Reports Q2 2025 Financial Results

August 13, 2025 | msn.com

ProKidney reports Q2 EPS (13c), consensus (14c)

August 12, 2025 | msn.com

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

August 12, 2025 | globenewswire.com

ProKidney Corp. (NASDAQ:PROK) Receives Consensus Rating of "Hold" from Analysts

August 10, 2025 | marketbeat.com

ProKidney Corp. (PROK) - Yahoo Finance

August 9, 2025 | finance.yahoo.com

ProKidney And 2 Other Penny Stocks To Watch Closely

August 7, 2025 | finance.yahoo.com

ProKidney (NASDAQ:PROK) Trading Down 10.5% - What's Next?

August 7, 2025 | marketbeat.com

ProKidney (NASDAQ:PROK) Stock Price Up 10% - Should You Buy?

August 1, 2025 | marketbeat.com

ProKidney (PROK) to Release Quarterly Earnings on Friday

August 1, 2025 | marketbeat.com

ProKidney (NASDAQ:PROK) Stock Price Down 7.8% - What's Next?

July 29, 2025 | marketbeat.com

ProKidney Stock Skyrockets But Greensboro Is Still Empty Handed

July 25, 2025 | rhinotimes.comR

ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement

July 22, 2025 | msn.com

Meet the Biotech Stock That Rocketed 775% Higher

July 22, 2025 | fool.com

ProKidney (NASDAQ:PROK) Shares Gap Up - Here's Why

July 21, 2025 | marketbeat.com

JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK)

July 20, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ACTU, DNTH, PROK, and GYRE Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

$7.66 -0.02 (-0.26%)

Closing price 04:00 PM Eastern

Extended Trading

$7.66 +0.00 (+0.07%)

As of 04:20 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Dianthus Therapeutics NASDAQ:DNTH

$23.65 +0.23 (+0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$23.89 +0.24 (+1.01%)

As of 05:13 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Gyre Therapeutics NASDAQ:GYRE

$7.55 -0.18 (-2.33%)

Closing price 04:00 PM Eastern

Extended Trading

$7.52 -0.02 (-0.33%)

As of 04:20 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

ProKidney NASDAQ:PROK

$2.32 +0.04 (+1.75%)

Closing price 04:00 PM Eastern

Extended Trading

$2.34 +0.02 (+0.65%)

As of 05:21 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time